Altria Group (MO) IV elevated into FDA denies authorization to market JUUL products
Tweet
Share
E-mail
Get Alerts MO Hot Sheet
Price: $43.54 +1.44%
Overall Analyst Rating:
NEUTRAL (
Up)
Dividend Yield: 9.1%
Revenue Growth %: -0.8%
Overall Analyst Rating:
NEUTRAL (
Up)Dividend Yield: 9.1%
Revenue Growth %: -0.8%
Join SI Premium – FREE
Altria Group (NYSE: MO) 30-day option implied volatility is at 33; compared to its 52-week range of 17 to 33 into FDA denies authorization to market JUUL products.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Altria Group (MO) April weekly option implied volatility into quarter results
- Altria (MO) delivers in-line earnings, revenue in Q1; shares slightly up
- Intel (INTC) call put ratio 3.2 calls to 1 put into quarter results
Create E-mail Alert Related Categories
OptionsRelated Entities
Options, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
